NasdaqCM - Nasdaq Real Time Price USD

Enveric Biosciences, Inc. (ENVB)

1.4650 +0.0250 (+1.74%)

As of 12:58:36 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study

Business Wire 6d ago

ENVB
+1.74%
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies

Business Wire 20d ago

ENVB
+1.74%
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Business Wire 1mo ago

ENVB
+1.74%
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Business Wire 2mo ago

ENVB
+1.74%
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Business Wire 3mo ago

ENVB
+1.74%
Enveric Biosciences Announces Participation in 2026 BIO International Convention

Business Wire 4mo ago

ENVB
+1.74%
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

PR Newswire 6mo ago

ENVB
+1.74%
LABT
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Business Wire 2mo ago

ENVB
+1.74%
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Business Wire 3mo ago

ENVB
+1.74%
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Business Wire 4mo ago

ENVB
+1.74%
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

Business Wire 5mo ago

ENVB
+1.74%
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

Business Wire 4mo ago

ENVB
+1.74%

Performance Overview

Return	ENVB	S&P 500 (^GSPC)
YTD	-59.64%	+9.30%
1-Year	-74.65%	+9.51%
3-Year	-99.97%	+69.46%

U.S. markets close in 2h 26m

Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study

Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2026 BIO International Convention

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day